Get the Stockscreener App
66.60
0.46%
-0.31
After Hours:
66.68
0.08
+0.12%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $66.60, with a volume of 5.12M.
It is down -0.46% in the last 24 hours and down -0.86% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$66.91
Open:
$67.78
24h Volume:
5.12M
Relative Volume:
0.93
Market Cap:
$206.53B
Revenue:
$51.21B
Net Income/Loss:
$6.50B
P/E Ratio:
31.94
EPS:
2.085
Net Cash Flow:
$6.76B
1W Performance:
-0.61%
1M Performance:
-0.86%
6M Performance:
-16.50%
1Y Performance:
+0.53%
1-Day Range:
$66.59
$67.78
1-Week Range:
$64.22
$67.78
52-Week Range:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
66.60 | 206.53B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman - GlobeNewswire Inc.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer - Yahoo Finance
US Dato-DXd Approval Relief For AstraZeneca and Daiichi Sankyo - News & Insights
2025-01-20 | Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN | NDAQ:AZN | Press Release - Stockhouse Publishing
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN - Stockhouse Publishing
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - PR Newswire
AstraZeneca gets first US approval for cancer treatment Datroway - ShareCast
AstraZeneca Plc Datroway approved in the US for metastatic breast cancer - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Oak Ridge Investments LLC - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC - GlobeNewswire
Professional Advisory Services Inc. Raises Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Position Cut by Boston Common Asset Management LLC - MarketBeat
AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector (NASDAQ:AZN) - Seeking Alpha
Procyon Advisors LLC Has $2.21 Million Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
23,847 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Empirical Asset Management LLC - MarketBeat
US FDA approves AstraZeneca's drug for breast cancer - Reuters.com
AstraZeneca, Daiichi Win FDA Approval for Breast Cancer Drug - Bloomberg
2025-01-17 | Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline - Benzinga
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
AstraZeneca rises Friday, still underperforms market - MarketWatch
AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma - Benzinga
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or - GlobeNewswire
AstraZeneca changes management of its China unit (AZN:NASDAQ) - Seeking Alpha
Faruqi & Faruqi Reminds AstraZeneca Investors of the - GlobeNewswire
AstraZeneca lymphoma drug gets expanded U.S. approval (AZN) - Seeking Alpha
AstraZeneca overhauls management of its China division, FT reports -January 17, 2025 at 09:12 am EST - Marketscreener.com
AstraZeneca overhauls management of its scandal-hit China division - Financial Times
Channel Wealth LLC Purchases 23,711 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca’s Calquence Wins FDA Approval for Mantle Cell Lymphoma - TipRanks
AstraZeneca's Calquence gains FDA nod for 1L MCL treatment - Investing.com
Ritholtz Wealth Management Cuts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
FDA grants full approval for AstraZeneca's Calquence - The Pharma Letter
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth - Pharmaceutical Technology
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
AstraZeneca drug for rare blood cancer gets US regulatory green light - Proactive Investors USA
AstraZeneca: Calquence approved for LCM by the FDA -January 17, 2025 at 03:00 am EST - Marketscreener.com
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
FDA approves AstraZeneca's Calquence for untreated mantle cell lymphoma By Investing.com - Investing.com UK
AstraZeneca's rare cancer drug Calquence gets US regulatory nod - ShareCast
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
AZN Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the AstraZeneca PLC Class Action - PR Newswire
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
AstraZeneca rises Thursday, outperforms market - MarketWatch
Shareholders that lost money on AstraZeneca PLC(AZN) should contact The Gross Law Firm about pending Class ActionAZN - Morningstar
Park Avenue Securities LLC Has $5.07 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Pines Wealth Management LLC Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Assenagon Asset Management S.A. Has $55.65 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):